Fabianne Nordenson, M.Sc. and M.A., is a Principal at Vivo Capital with a background in healthcare investing and drug discovery research. Before joining Vivo, Fabianne worked at Roivant Pharma where she was responsible for investments in preclinical and clinical stage therapeutics. Prior to Roivant, Fabianne worked at Cowen where she was an investment banker on the healthcare team. There, Fabianne worked on equity transactions for private and public biotech companies. Fabianne started her Wall Street career in the healthcare equity research team at Cantor Fitzgerald.
Prior to Cantor Fitzgerald, Fabianne worked at Weill Cornell Medical College where she conducted drug discovery research in oncology. Before Cornell, Fabianne was at Harvard Medical School where she was a fellow responsible for multiple oncology research projects. She is published in multiple peer-reviewed journals, including PLOS One, the Journal of the American Chemical Society and the Journal of Organic Chemistry.
Mrs. Nordenson received her B.S. in Chemistry, Biotechnology and Cell Science from the University of Florida, her M.Sc. in Medicinal Chemistry from the University of California, Irvine, and her M.A. in Finance from Harvard University.